A Randomised Trial of Adriamycin and Taxotere vs. Adriamycin and Cyclophosphamide in Breast Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15113276

Enrollment

363

Registered

2002-08-19

Start date

1999-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

1. Adriamycin 50 mg/m^2 intravenous (iv) 3 weekly + taxotere 75 mg/m^2 iv 3 weekly (NB Taxotere must be administered prior to Adriamycin) 2. Adriamycin (60 mg/m^2 iv) 3 weekly + cyclophosphamide (600

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically proven breast cancer (BrCa) 2. Potentially operable disease >3cm diameter, locally advanced disease (including T4 lesions) or inflammatory BrCa 3. Patients older then 18 years

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Added 12/02/10: Overall (complete and partial) clinical response rates	—

Secondary

Measure	Time frame
Added 12/02/10: Number of relapses	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026